Guilin Rheinland Biotechnology Co., Ltd. Q1 2026 Report Stock code: 002166 Stock abbreviation: Rhein Biotech Announcement number: 2026-023 Guilin Rhein Biotechnology Co., Ltd Q1 2026 Report The Company and all members of the Board of Directors guarantee that the content of the information disclosure is true, accurate and complete, and there are no false records or errors Leading statements or material omissions. Important Content Tips:
- The board of directors, directors and senior management ensure that the quarterly report is true, accurate and complete, and there are no false records Misleading statements or material omissions, and bear individual and joint legal liabilities.
- The person in charge of the company, the person in charge of accounting work and the person in charge of the accounting institution (accounting supervisor) declare: guarantee The financial information in the quarterly report is true, accurate and complete.
- Whether the financial accounting report for the first quarter has been audited □ Yes No
- Main financial data (1) Main accounting data and financial indicators Whether the company needs to retroactively adjust or restate the accounting data of previous years □ Yes No The reporting period is the same as that of the previous year
This reporting period is the same period of the previous year Periodic increase or decrease (%) Operating income (yuan) 446,871,087.43 444,292,336.62 0.58% Net profit attributable to shareholders of listed companies (yuan) 42,516,534.18 30,794,889.80 38.06% Net profit attributable to shareholders of listed companies after deducting non-recurring gains and losses (yuan) 40,328,168.97 36,135,337.34 11.60% Net cash flow from operating activities (yuan) 312,870,193.21 182,936,113.99 71.03% Basic earnings per share (yuan/share) 0.0573 0.0418 37.08% Diluted earnings per share (yuan/share) 0.0573 0.0418 37.08% Weighted average return on equity 1.34% 0.99% 0.35%
The end of the reporting period was higher than that of the previous year